A Phase 3 interventional study of Gemcitabine and Placebo in Bladder Neoplasms, sponsored by Eli Lilly and Company. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies testing gemcitabine in Urinary Bladder Neoplasms — 12 open to participants now, 23 under way, 3 of them phase 3. Gemcitabine · Urinary Bladder Neoplasms.
Among the 101 studies testing gemcitabine in Urinary Bladder Neoplasms, this one is the 5th largest by enrollment of the 96 interventional ones that give a count, is one of 3 that started in 2004, is one of 13 in phase 3, and was the 29th registered.
1,801 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →12 of the 101 studies testing gemcitabine in Urinary Bladder Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 20+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 337 Urinary Bladder Neoplasms studies recruiting now, 257 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 73 · Phase 3 14 · Phase 4 1
First in 1997; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 355 is above the median of 60 across 1,297 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 42 across the 96 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 101 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
14 studies in Urinary Bladder Neoplasms by Eli Lilly and Company: 4 open now, 5 under way, 1 of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 14 studies in Urinary Bladder Neoplasms by Eli Lilly and Company, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2004, is one of 3 in phase 3, and was the 3rd registered.
Eli Lilly and Company’s Urinary Bladder Neoplasms studies by the year they started, since 2003.
8 of the studies testing gemcitabine in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06364904Phase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityA Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. | 2027-04-15 |
| NCT02989584Memorial Sloan Kettering Cancer CenterA Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | 2026-12 |
| NCT05975307Sun Yat-sen UniversityTreating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation | 2026-12-31 |
| NCT05024734Roland Seiler-BlarerGuiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids | 2026-12-31 |
| NCT06488222University of FloridaIntravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer | 2027-08 |
Add all 8 to your calendar (.ics) → With an account.
Among the 101 studies testing gemcitabine in Urinary Bladder Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 14 in Urinary Bladder Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gemcitabine
Drug: Placebo
2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
Also known as: LY 188011, Gemzar
intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
Recurrence-Free Survival (RFS)
Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.
Time frame: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Time to Recurrence
Time from enrollment to first confirmation of histopathological recurrence or disease progression. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence.
Time frame: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Recurrence-Free Survival (RFS) in Subgroups
Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.
Time frame: Surgery to recurrence or death (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
Tumor Recurrence Type
Tumor recurrence type (superficial, stage pTA or pT1; or muscle-invasive, stage≥pT2) was classified according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer (AJCC Cancer Staging Manual, 6th edition).
Time frame: Surgery to recurrence (Follow-up assessments were performed at 3 and 6 months after the first TUR-BT, and every 6 months thereafter, until recurrence/progression of disease, or until the end of study, up to 24 months)
| Milestone | Gemcitabine | Placebo |
|---|---|---|
| Started | 179 | 176 |
| Received study drug | 166 | 162 |
| Completed | 41 | 47 |
| Not completed | 138 | 129 |
| Withdrew: Tumor recurrence | 49 | 48 |
| Withdrew: Death, study disease | 1 | 1 |
| Withdrew: Death, other cause | 3 | 6 |
| Withdrew: Lost to follow-up | 23 | 21 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Treatment change | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Other | 2 | 0 |
| Withdrew: Not eligible | 41 | 38 |
| Withdrew: Pathological specimen lost | 1 | 0 |
| Withdrew: Discontinued prior to instillation | 13 | 14 |
Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival (RFS) was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.
| Months | Gemcitabine | Placebo |
|---|---|---|
| Recurrence-Free Survival (RFS) | 37.2 (0.0 to 45.9) | 40.2 (0.0 to 42.2) |
Because median time to recurrence was not reached, percentage of participants without event was estimated using Kaplan-Meier method. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence.
| percentage of participants | Gemcitabine | Placebo |
|---|---|---|
| Recurrence-Free at 12 Months | 78.4 (56.4 to 74.5) | 76.9 (53.9 to 71.9) |
| Recurrence-Free at 24 Months | 66.3 | 63.7 |
RFS rate was estimated using Kaplan-Meier method. RFS was analyzed in different subgroups based on risk, disease status, and concomitant Bacillus Calmette-Guerin (BCG) instillations. Risk: Grading (G1,G2,G3) was performed according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer. Newly diagnosed disease: Initial diagnosis at study entry. Recurrent disease: history of at least one superficial bladder tumor that was surgically treated and relapsed prior to study entry. With BCG: received at least one instillation of BCG during study. Without BCG: didn't receive BCG.
| percentage of participants | Gemcitabine | Placebo |
|---|---|---|
| Low Risk (G1/G2) - 12 Months (N=106, N=109) | 78.5 (68.9 to 85.4) | 78.4 (69.1 to 85.2) |
| Low Risk (G1/G2) - 24 Months (N=106, N=109) | 63.9 | 64.3 |
| High Risk (G3) - 12 Months (N=13, N=14) | 66.7 (33.7 to 86.0) | 42.4 (13.7 to 69.1) |
| High Risk (G3) - 24 Months (N=13, N=14) | 57.1 | 31.8 |
| Newly Diagnosed Disease - 12 Months (N=94, N=98) | 79.3 (69.1 to 86.4) | 79.8 (69.9 to 86.8) |
| Newly Diagnosed Disease - 24 Months (N=94, N=98) | 65.4 | 63.6 |
| Recurrent Disease - 12 Months (N=30, N=26) | 72.2 (50.4 to 85.7) | 58.9 (37.1 to 75.5) |
| Recurrent Disease - 24 Months (N=30, N=26) | 59.5 | 50.5 |
| With BCG - 12 Months (N=13, N=21) | 61.5 (30.8 to 81.8) | 79.4 (54.0 to 91.7) |
| With BCG - 24 Months (N=13, N=21) | 49.2 | 63.5 |
| Without BCG - 12 Months (N=111, N=103) | 79.9 (70.6 to 86.6) | 74.5 (64.4 to 82.1) |
| Without BCG - 24 Months (N=111, N=103) | 65.8 | 60.1 |
Time from enrollment to first confirmation of histopathological recurrence or disease progression. Time to recurrence was censored on date of death for patients who died, and on date of last visit for patients who were alive, without recurrence.
No measurements were reported for this outcome.
Defined as the time from study enrollment to the date of the first procedure confirming histopathological recurrence or disease progression or death from any cause. Recurrence-free survival was censored at the date of the last follow-up visit for participants who were still alive and who had no recurrence/progression.
No measurements were reported for this outcome.
Tumor recurrence type (superficial, stage pTA or pT1; or muscle-invasive, stage≥pT2) was classified according to American Joint Committee on Cancer Staging Criteria for Bladder Cancer (AJCC Cancer Staging Manual, 6th edition).
| participants | Gemcitabine | Placebo |
|---|---|---|
| No Tumor Recurrence | 76 | 78 |
| Superficial Tumor - Stage pTa or pT1 | 44 | 45 |
| Muscle-Invasive Tumor - Any Stage ≥pT2 | 3 | 1 |
| pTx - Tumor Cannot be Assessed | 1 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine | — | 17/166 (10.2%) | 38/166 (22.9%) |
| Placebo | — | 10/162 (6.2%) | 36/162 (22.2%) |
| Event | Gemcitabine | Placebo |
|---|---|---|
| Urinary bladder excisionSurgical and medical procedures | 8/166 | 5/162 |
| Septic shockInfections and infestations | 0/166 | 1/162 |
| Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/166 | 1/162 |
| Renal colicRenal and urinary disorders | 0/166 | 1/162 |
| Urinary bladder haemorrhageRenal and urinary disorders | 0/166 | 1/162 |
| CystoprostatectomySurgical and medical procedures | 1/166 | 1/162 |
| Angina pectorisCardiac disorders | 1/166 | 0/162 |
| Enterovesical fistulaGastrointestinal disorders | 1/166 | 0/162 |
| Inguinal herniaGastrointestinal disorders | 1/166 | 0/162 |
| PyelonephritisInfections and infestations | 1/166 | 0/162 |
| Event | Gemcitabine | Placebo |
|---|---|---|
| PainGeneral disorders | 0/166 | 5/162 |
| CystitisInfections and infestations | 2/166 | 5/162 |
| Bladder painRenal and urinary disorders | 5/166 | 3/162 |
| Bladder spasmRenal and urinary disorders | 1/166 | 4/162 |
| Procedural painInjury, poisoning and procedural complications | 4/166 | 0/162 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/166 | 3/162 |
| Sleep disorderPsychiatric disorders | 1/166 | 3/162 |
| PyrexiaGeneral disorders | 3/166 | 1/162 |
| HeadacheNervous system disorders | 3/166 | 0/162 |
| Neck painMusculoskeletal and connective tissue disorders | 0/166 | 2/162 |
| Age Continuous(years) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| Mean | 63.2 ± 11.9 | 66.3 ± 11.0 | 64.7 ± 11.5 |
| Sex: Female, Male(Participants) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| Female | 39 | 26 | 65.0 |
| Male | 127 | 136 | 263.0 |
| Region of Enrollment(participants) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| Germany | 131 | 126 | 257.0 |
| Turkey | 35 | 36 | 71.0 |
| Karnofsky Performance Status(participants) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| 70 - Unable to carry on normal activity | 1 | 1 | 2.0 |
| 80 - Activity with effort; some signs of disease | 13 | 7 | 20.0 |
| 90 - Normal activity; minor signs of disease | 33 | 49 | 82.0 |
| 100 - Normal no complaints; no evidence of disease | 118 | 104 | 222.0 |
| Unspecified | 1 | 1 | 2.0 |
| Newly Diagnosed versus Recurrent Disease(participants) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| Recurrent Disease | 43 | 40 | 83.0 |
| Newly Diagnosed | 123 | 122 | 245.0 |
| Race/Ethnicity(participants) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| White | 166 | 162 | 328 |
| Results of Initial Transurethral Resection of a Bladder Tumor (TUR-BT): Number of Visible Lesions(participants) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| No Lesions (No Specific Sites Documented) | 4 | 5 | 9.0 |
| 1 Lesion | 87 | 96 | 183.0 |
| 2 Lesions | 42 | 27 | 69.0 |
| 3 Lesions | 18 | 14 | 32.0 |
| 4 Lesions | 7 | 10 | 17.0 |
| >=5 Lesions | 8 | 10 | 18.0 |
| Results of Transurethral Resection of Bladder Tumor (TUR-BT): Final Pathological Disease Stage(participants) | Gemcitabine | Placebo | Total |
|---|---|---|---|
| pTx: Primary Tumor Cannot be Assessed | 3 | 0 | 3.0 |
| pT0: No Evidence of Primary Tumor | 0 | 0 | 0.0 |
| pTa: Noninvasive Papillary Carcinoma | 93 | 88 | 181.0 |
| pT1: Tumor Invades Subepithelial Connective Tissue | 31 | 36 | 67.0 |
| >=pT2: Tumor Invades Wider Area | 12 | 10 | 22.0 |
| Cis: Carcinoma in situ ("Flat Tumor") | 5 | 6 | 11.0 |
| No Malignancy | 21 | 22 | 43.0 |
| Unspecified | 1 | 0 | 1.0 |
1 further baseline measures are reported on the registry.
The record gives a start of Jan 2004, a primary completion of Mar 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine